...
首页> 外文期刊>Human vaccines & immunotherapeutics. >Fatal varicella due to the vaccine-strain varicella-zoster virus
【24h】

Fatal varicella due to the vaccine-strain varicella-zoster virus

机译:疫苗株水痘带状疱疹病毒致死的水痘

获取原文
获取原文并翻译 | 示例

摘要

We describe a death in a 15-mo-old girl who developed a varicella-like rash 20 d after varicella vaccination that lasted for 2 mo despite acyclovir treatment. The rash was confirmed to be due to vaccine-strain varicella-zoster virus (VZV). This is the first case of fatal varicella due to vaccine-strain VZV reported from the United States. The patient developed severe respiratory complications that worsened with each new crop of varicella lesions; vaccine-strain VZV was detected in the bronchial lavage specimen. Sepsis and multi-organ failure led to death. The patient did not have a previously diagnosed primary immune deficiency, but her failure to thrive and repeated hospitalizations early in life (starting at 5 mo) for presumed infections and respiratory compromise treated with corticosteroids were suggestive of a primary or acquired immune deficiency. Providers should monitor for adverse reactions after varicella vaccination. If severe adverse events develop, acyclovir should be administered as soon as possible. The possibility of acyclovir resistance and use of foscar-net should be considered if lesions do not improve after 10 d of treatment (or if they become atypical [e. g., verrucous]). Experience with use of varicella vaccine indicates that the vaccine has an excellent safety profile and that serious adverse events are very rare and mostly described in immunocompromised patients. The benefit of vaccination in preventing severe disease and mortality outweigh the low risk of severe events occurring after vaccination.
机译:我们描述了一名15个月大的女孩的死亡,该女孩在接受水痘疫苗接种后20 d出现了水痘样皮疹,尽管使用阿昔洛韦治疗仍持续2个月。确认皮疹是由于疫苗株水痘带状疱疹病毒(VZV)引起的。这是美国报道的首例因疫苗株VZV致死的水痘。患者出现严重的呼吸系统并发症,每出现一新的水痘病灶就会恶化。在支气管灌洗标本中检测到疫苗株VZV。败血症和多器官衰竭导致死亡。该患者先前没有被诊断为原发性免疫缺陷,但是由于推测的感染和皮质类固醇激素治疗而导致呼吸衰竭,生命早期(从5个月开始)and壮成长和反复住院失败,提示该患者患有原发性或获得性免疫缺陷。提供者应监测水痘疫苗接种后的不良反应。如果发生严重不良事件,应尽快服用阿昔洛韦。如果在治疗10天后病灶没有改善(或病灶变得不典型[例如疣状]),则应考虑使用阿昔洛韦抗药性和使用foscar-net。使用水痘疫苗的经验表明,该疫苗具有出色的安全性,严重的不良事件非常罕见,并且大多在免疫功能低下的患者中得到描述。预防严重疾病和死亡的预防接种的好处超过了预防接种后发生严重事件的低风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号